Generics for Jardiance Duo, a diabetes treatment complex affiliated with SGLT-2 inhibition of Beringer Ingelheim, have been approved.

On the 4th and 5th, the MFDS approved 76 items of Empagliflozin/Metformin HCl from 26 pharmaceutical companies. Generics for Jardiance Duo are commissioned by Dongkoo Bio.

Empagliflozin/ Metformin for the original Jardiance Duo, which expired on March 11, 2025, but Chong Kun Dang succeeded in avoiding the patent by challenging the crystalline patent of Jardiance and Jardiance Duo, which ends on December 14, 2026. In January 2018, it was the first Korean company to request a passive judgment on the scope of rights, and the decision to establish some of them